Analysts See $-0.01 EPS for HLS Therapeutics Inc. (HLS)

November 10, 2018 - By Jeanette Kaplan

Analysts expect HLS Therapeutics Inc. (CVE:HLS) to report $-0.01 EPS on November, 21.After having $-0.03 EPS previously, HLS Therapeutics Inc.’s analysts see -66.67 % EPS growth. The stock decreased 0.06% or $0.01 during the last trading session, reaching $16.09. About 111,475 shares traded or 86.68% up from the average. HLS Therapeutics Inc. (CVE:HLS) has 0.00% since November 11, 2017 and is . It has underperformed by 15.62% the S&P500.

HLS Therapeutics Inc., a specialty pharmaceutical company, acquires and distributes pharmaceutical products in North American markets. The company has market cap of $439.73 million. It is focused on treatment products for the central nervous system and cardiovascular specialties. It currently has negative earnings.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.